Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PERRIGO Co plcPRGO · Entity 4516 | Director | September 13, 2024 | September 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PERRIGO Co plc
Report date September 13, 2024 · Filed September 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 6,009 |
Reported balance
After 2024-09-13 transaction · row 1
1 source rowRow 1 · 2024-09-13 · Sale · Disposed 8,954 · Balance 6,009 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABBOTT LABORATORIES
Report date October 31, 2013 · Filed March 13, 2015
Section 16 reporting ended · disclosed 2015-03-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 43,474 |
Ending reported balance
After 2014-04-15 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2013-10-31 · Purchase · Acquired 102 · Balance 43,429 F1: Purchase was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the reporting person's sale of 200 shares of Abbott common shares at a price of $39.015 per share (including transaction costs), or $38.999 per share (excluding transaction costs), which was reported on March 4, 2014. The reporting person has paid to Abbott $239.70, representing the full amount of the profit realized in connection with these transactions, less transaction costs. Row 2 · 2013-12-03 · Purchase · Acquired 4 · Balance 43,433 F1: Purchase was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the reporting person's sale of 200 shares of Abbott common shares at a price of $39.015 per share (including transaction costs), or $38.999 per share (excluding transaction costs), which was reported on March 4, 2014. The reporting person has paid to Abbott $239.70, representing the full amount of the profit realized in connection with these transactions, less transaction costs. Row 3 · 2014-02-03 · Sale · Disposed 1 · Balance 43,432 Row 4 · 2014-03-14 · Purchase · Acquired 52 · Balance 43,484 Row 5 · 2014-04-15 · Sale · Disposed 10 · Balance 43,474 |
Filing footnotes · ownership attribution and instrument terms
F1: Purchase was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the reporting person's sale of 200 shares of Abbott common shares at a price of $39.015 per share (including transaction costs), or $38.999 per share (excluding transaction costs), which was reported on March 4, 2014. The reporting person has paid to Abbott $239.70, representing the full amount of the profit realized in connection with these transactions, less transaction costs.
BEMIS CO INC
Report date June 11, 2019 · Filed June 11, 2019
Section 16 reporting ended · disclosed 2019-06-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-06-11 transaction · row 1
1 source rowRow 1 · 2019-06-11 · Disposition to issuer · Disposed 5,851 · Balance 0 F1: Disposed of as a result of merger pursuant to the previously announced Transaction Agreement, dated as of August 6, 2018 (which, as it may be amended from time to time, we refer to as the "Transaction Agreement"), by and among Amcor plc (f/k/a Arctic Jersey Limited)("New Amcor"), Amcor Limited, Arctic Corp. and Bemis Company, Inc. F2: Includes 96 shares acquired pursuant to a dividend equivalent feature upon settlement of a restricted stock unit. F3: Each share of common stock was cancelled pursuant to the Transaction Agreement in exchange for the right to receive the consideration provided in the Transaction Agreement (i.e., 5.1 ordinary shares of New Amcor for each such share, subject to applicable tax withholding and with cash payable in lieu of any fractional shares). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of as a result of merger pursuant to the previously announced Transaction Agreement, dated as of August 6, 2018 (which, as it may be amended from time to time, we refer to as the "Transaction Agreement"), by and among Amcor plc (f/k/a Arctic Jersey Limited)("New Amcor"), Amcor Limited, Arctic Corp. and Bemis Company, Inc.
F2: Includes 96 shares acquired pursuant to a dividend equivalent feature upon settlement of a restricted stock unit.
F3: Each share of common stock was cancelled pursuant to the Transaction Agreement in exchange for the right to receive the consideration provided in the Transaction Agreement (i.e., 5.1 ordinary shares of New Amcor for each such share, subject to applicable tax withholding and with cash payable in lieu of any fractional shares).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2024 Filed Sep 13, 2024 15:28 UTC | PERRIGO Co plc PRGO · Entity 4516 | SaleOrdinary Shares | 8,954 | $27.30 | $244,444.20 |
DisclosureSEC source: 0001585364-24-000128 · wk-form4_1726255730.xml · nonDerivative · entry 1 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,009 Read SEC document |
| May 15, 2024 Filed May 16, 2024 19:27 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionRestricted Stock Units · Derivative | 8,764 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-24-000088 · wk-form4_1715902059.xml · derivative · entry 4 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,764 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 15 May 2024. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 15 May 2024. Read SEC document |
| May 15, 2024 Filed May 16, 2024 19:27 UTC | PERRIGO Co plc PRGO · Entity 4516 | Tax withholdingOrdinary Shares | 4,207 | $30.22 | $127,135.54 |
DisclosureSEC source: 0001585364-24-000088 · wk-form4_1715902059.xml · nonDerivative · entry 2 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,963 Read SEC document |
| May 15, 2024 Filed May 16, 2024 19:27 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionOrdinary Shares | 8,764 | $30.22 | $264,848.08 |
DisclosureSEC source: 0001585364-24-000088 · wk-form4_1715902059.xml · nonDerivative · entry 1 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2024 Filed May 16, 2024 19:27 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 9,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-24-000088 · wk-form4_1715902059.xml · derivative · entry 3 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,904 Underlying: Ordinary Shares · 9,904 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025. Read SEC document |
| May 17, 2023 Filed May 19, 2023 14:39 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionRestricted Stock Units · Derivative | 7,778 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-23-000099 · wf-form4_168452155003988.xml · derivative · entry 3 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · kind: Vesting of service-based restricted stock units granted on 17 May 2022. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2023. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2023. Read SEC document |
| May 17, 2023 Filed May 19, 2023 14:39 UTC | PERRIGO Co plc PRGO · Entity 4516 | Tax withholdingOrdinary Shares | 3,734 | $32.86 | $122,699.24 |
DisclosureSEC source: 0001585364-23-000099 · wf-form4_168452155003988.xml · nonDerivative · entry 2 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,406 Read SEC document |
| May 17, 2023 Filed May 19, 2023 14:39 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionOrdinary Shares | 7,778 | $32.86 | $255,585.08 |
DisclosureSEC source: 0001585364-23-000099 · wf-form4_168452155003988.xml · nonDerivative · entry 1 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on 17 May 2022. Read SEC document |
| May 15, 2023 Filed May 17, 2023 15:42 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 8,764 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-23-000079 · wf-form4_168435251099771.xml · derivative · entry 2 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,764 Underlying: Ordinary Shares · 8,764 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 15 May 2024. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 15 May 2024. Read SEC document |
| May 17, 2022 Filed May 19, 2022 13:54 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionRestricted Stock Units · Derivative | 6,599 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-22-000058 · wf-form4_165298286787814.xml · derivative · entry 4 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · kind: Vesting of service-based restricted stock units granted on 17 May 2021. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2022. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2022. Read SEC document |
| May 17, 2022 Filed May 19, 2022 13:54 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 7,778 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-22-000058 · wf-form4_165298286787814.xml · derivative · entry 3 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,778 Underlying: Ordinary Shares · 7,778 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2023. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2023. Read SEC document |
| May 17, 2022 Filed May 19, 2022 13:54 UTC | PERRIGO Co plc PRGO · Entity 4516 | Tax withholdingOrdinary Shares | 3,168 | $38.57 | $122,189.76 |
DisclosureSEC source: 0001585364-22-000058 · wf-form4_165298286787814.xml · nonDerivative · entry 2 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,362 Read SEC document |
| May 17, 2022 Filed May 19, 2022 13:54 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionOrdinary Shares | 6,599 | $38.57 | $254,523.43 |
DisclosureSEC source: 0001585364-22-000058 · wf-form4_165298286787814.xml · nonDerivative · entry 1 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on 17 May 2021. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 12:02 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionRestricted Stock Units · Derivative | 5,637 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-21-000104 · wf-form4_162912971764121.xml · derivative · entry 3 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,637 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · kind: Vesting of service-based restricted stock units granted on 12 August 2020. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 12 August 2021. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 12 August 2021. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 12:02 UTC | PERRIGO Co plc PRGO · Entity 4516 | Tax withholdingOrdinary Shares | 2,706 | $41.28 | $111,703.68 |
DisclosureSEC source: 0001585364-21-000104 · wf-form4_162912971764121.xml · nonDerivative · entry 2 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,931 Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 12:02 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionOrdinary Shares | 5,637 | $41.28 | $232,695.36 |
DisclosureSEC source: 0001585364-21-000104 · wf-form4_162912971764121.xml · nonDerivative · entry 1 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,637 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on 12 August 2020. Read SEC document |
| May 17, 2021 Filed May 19, 2021 12:57 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 6,599 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-21-000080 · wf-form4_162144346483320.xml · derivative · entry 2 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,599 Underlying: Ordinary Shares · 6,599 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting in 3 equal annual installments beginning 17 May 2022. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting in 3 equal annual installments beginning 17 May 2022. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 12:16 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 5,637 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-20-000087 · wf-form4_159742176367441.xml · derivative · entry 2 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,637 Underlying: Ordinary Shares · 5,637 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 12 August 2021. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 12 August 2021. Read SEC document |
| June 11, 2019 Filed Jun 11, 2019 16:23 UTC | BEMIS CO INC BMS · Entity 156671 | Disposition to issuerCommon Stock | 5,851 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-007488 · edgar.xml · nonDerivative · entry 1 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of as a result of merger pursuant to the previously announced Transaction Agreement, dated as of August 6, 2018 (which, as it may be amended from time to time, we refer to as the "Transaction Agreement"), by and among Amcor plc (f/k/a Arctic Jersey Limited)("New Amcor"), Amcor Limited, Arctic Corp. and Bemis Company, Inc. F2 · shares: Includes 96 shares acquired pursuant to a dividend equivalent feature upon settlement of a restricted stock unit. F3 · price: Each share of common stock was cancelled pursuant to the Transaction Agreement in exchange for the right to receive the consideration provided in the Transaction Agreement (i.e., 5.1 ordinary shares of New Amcor for each such share, subject to applicable tax withholding and with cash payable in lieu of any fractional shares). Read SEC document |
| May 03, 2018 Filed May 4, 2018 13:27 UTC | BEMIS CO INC BMS · Entity 156671 | GrantCommon Stock | 3,095 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006232 · edgar.xml · nonDerivative · entry 1 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,676 F1 · shares: Restricted stock unit granted to Bemis Director pursuant to 2014 Stock Incentive Plan exempt under Rule 16b-3: Grant made on May 3, 2018, as part of Director's Annual Fee, vests on the earlier of May 2, 2019 or 2019 annual meeting of shareholders. F2 · balance_after: Includes 51 shares acquired pursuant to a dividend equivalent feature upon settlement of a restricted stock unit. Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 17:31 UTC | BEMIS CO INC BMS · Entity 156671 | GrantCommon Stock | 2,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-011157 · edgar.xml · nonDerivative · entry 1 Doyle Katherine C. · CIK 0001570003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,530 F1 · shares: Restricted stock unit granted to Bemis Director pursuant to 2014 Stock Incentive Plan exempt under Rule 16b-3: Grant made on August 2, 2017, as part of pro-rated Director's Annual Fee, vests on the earlier of May 3, 2018 or 2018 annual meeting of shareholders. Read SEC document |
| May 23, 2014 Filed May 27, 2014 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,198 | $39.65 | $166,450.70 |
DisclosureSEC source: 0001179110-14-009225 · edgar.xml · nonDerivative · entry 1 Doyle Katherine C. · CIK 0001570003 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,327 Read SEC document |
| April 15, 2014 Filed Mar 13, 2015 21:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10 | $37.58 | $375.82 |
DisclosureSEC source: 0001179110-15-004891 · edgar.xml · nonDerivative · entry 5 Doyle Katherine C. · CIK 0001570003 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,474 Read SEC document |
| March 14, 2014 Filed Mar 13, 2015 21:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 52 | $39.11 | $2,033.51 |
DisclosureSEC source: 0001179110-15-004891 · edgar.xml · nonDerivative · entry 4 Doyle Katherine C. · CIK 0001570003 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,484 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $39.02 | $7,803.00 |
DisclosureSEC source: 0001179110-14-004297 · edgar.xml · nonDerivative · entry 5 Doyle Katherine C. · CIK 0001570003 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,525 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 900 | $39.01 | $35,109.90 |
DisclosureSEC source: 0001179110-14-004297 · edgar.xml · nonDerivative · entry 4 Doyle Katherine C. · CIK 0001570003 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,725 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,888 | $39.01 | $151,655.33 |
DisclosureSEC source: 0001179110-14-004297 · edgar.xml · nonDerivative · entry 3 Doyle Katherine C. · CIK 0001570003 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,625 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,651 | $39.00 | $64,395.60 |
DisclosureSEC source: 0001179110-14-004297 · edgar.xml · nonDerivative · entry 2 Doyle Katherine C. · CIK 0001570003 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,513 Read SEC document |
| February 28, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,043 | $39.79 | $160,870.97 |
DisclosureSEC source: 0001179110-14-004297 · edgar.xml · nonDerivative · entry 1 Doyle Katherine C. · CIK 0001570003 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,164 Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 87,061 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001179110-14-003603 · edgar.xml · derivative · entry 2 Doyle Katherine C. · CIK 0001570003 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,061 Underlying: Common shares · 87,061 shares Expires 2024-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 29,021 on 2/21/2015, 29,020 on 2/21/2016, and 29,020 on 2/21/2017. Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 14,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-003603 · edgar.xml · nonDerivative · entry 1 Doyle Katherine C. · CIK 0001570003 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,207 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 03, 2014 Filed Mar 13, 2015 21:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1 | $35.93 | $35.93 |
DisclosureSEC source: 0001179110-15-004891 · edgar.xml · nonDerivative · entry 3 Doyle Katherine C. · CIK 0001570003 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,432 Read SEC document |
| December 03, 2013 Filed Mar 13, 2015 21:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 4 | $37.50 | $150.00 |
DisclosureSEC source: 0001179110-15-004891 · edgar.xml · nonDerivative · entry 2 Doyle Katherine C. · CIK 0001570003 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,433 F1 · shares: Purchase was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the reporting person's sale of 200 shares of Abbott common shares at a price of $39.015 per share (including transaction costs), or $38.999 per share (excluding transaction costs), which was reported on March 4, 2014. The reporting person has paid to Abbott $239.70, representing the full amount of the profit realized in connection with these transactions, less transaction costs. Read SEC document |
| October 31, 2013 Filed Mar 13, 2015 21:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 102 | $36.71 | $3,744.22 |
DisclosureSEC source: 0001179110-15-004891 · edgar.xml · nonDerivative · entry 1 Doyle Katherine C. · CIK 0001570003 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,429 F1 · shares: Purchase was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the reporting person's sale of 200 shares of Abbott common shares at a price of $39.015 per share (including transaction costs), or $38.999 per share (excluding transaction costs), which was reported on March 4, 2014. The reporting person has paid to Abbott $239.70, representing the full amount of the profit realized in connection with these transactions, less transaction costs. Read SEC document |
| May 23, 2013 Filed May 28, 2013 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,982 | $37.72 | $112,481.04 |
DisclosureSEC source: 0001179110-13-009243 · edgar.xml · nonDerivative · entry 1 Doyle Katherine C. · CIK 0001570003 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,987 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.